A peptide that ameliorates lupus up-regulates the diminished expression of early growth response factors 2 and 3

Journal of Immunology

Volumn 180, Issue 3, 2008, Pages 1584-1591

  Sela, Uri ^a,b   Dayan, Molly ^a   Hershkoviz, Rami ^b   Lider, Ofer ^a   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; DNA ANTIBODY; EARLY GROWTH RESPONSE FACTOR 2; EARLY GROWTH RESPONSE FACTOR 3; EDRATIDE; GAMMA INTERFERON; HUMAN MONOCLONAL ANTIBODY; INHIBITOR OF DIFFERENTIATION PROTEIN; INTERLEUKIN 1; MESSENGER RNA; PEPTIDE; PROTEIN KINASE B; RECOMBINANT INTERLEUKIN 2; SERYLLYSYLGLYCYLISOLEUCYLPROLYLGLUTAMINYLTYROSYLGLYCYLGLYCYLTRYPTOPHYL PROLYLTRYPTOPHYLGLUTAMYLTRYPTOPHYLARGINYLTHREONYLGLUTAMYLISOLEUCINE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT; PHOSPHATIDYLINOSITOL 3 KINASE; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; ENZYME PHOSPHORYLATION; FEMALE; IMMUNIZATION; IMMUNOMODULATION; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NEW ZEALAND BLACK MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; UPREGULATION; ANIMAL; CLONAL ANERGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE STRAIN; PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIBODIES, MONOCLONAL; CLONAL ANERGY; EARLY GROWTH RESPONSE PROTEIN 2; EARLY GROWTH RESPONSE PROTEIN 3; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED STRAINS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-CBL; RECOMBINANT PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 40749118892     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.3.1584     Document Type: Article

References (36)

1. O'Donovan, K. J., W. G. Tourtellote, J. Millbrandt, and J. M. Baraban. 1999. The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience. Trends Neurosci. 22: 167-173.
2. Safford, M., S. Collins, M. A. Lutz, A. Allen, C. T. Huang, J. Kowalski, A. Blackford, M. R. Horton, C. Drake, H. Schwartz, and J. D. Powell. 2005. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat. Immunol. 6: 472-480.
3. + T cells. J. Immunol. 173: 7331-7338.
4. Mueller, D. L. 2004. E3 ubiquitin ligases as T cell anergy factors. Nat. Immunol. 5: 883-890.
5. Schwartz, R. H. 2003. T cell anergy. Annu. Rev. Immunol. 21: 305-334.
6. Kane, L. P., P. J. Andres, K. C. Howland, A. K. Abbas, and A. Weiss. 2001. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-γ but not TH2 cytokines. Nat. Immunol. 2: 37-44.
7. Sanchez-Martin, L., N. Sanchez-Sanchez, M. D. Gutierrez-Lopez, A. I. Rojo, M. Vicente-Manzanares, M. J. Perez-Alvarez, P. Sanchez-Mateos, X. R. Bustelo, A. Cuadrado, F. Sanchez-Madrid, et al. 2004. Signaling through the leukocyte integrin LFA-1 in T cells induces a transient activation of Rac-1 that is regulated by Vav and PI3K/Akt-1. J. Biol. Chem. 279: 16194-16205.
8. short via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur. J. Immunol. 35: 1257-1266.
9. Kane, L. P., and A. Weiss. 2003. The PI-3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3. Immunol. Rev. 192: 7-20.
10. Lang, T. J., P. Nguyen, J. C. Papadimitriou, and C. S. Via. 2003. Increased severity of murine lupus in female mice is due to enhanced expansion of pathogenic T cells. J. Immunol. 171: 5795-5801.
11. Sherer, Y., A. Gorstein, M. J. Fritzler, and Y. Shoenfeld. 2004. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin. Arthritis Rheum. 34: 501-537.
12. Zhou, G., K. Fujio, A. Sadakata, A. Okamoto, R. Yu, and K. Yamamoto. 2004. Identification of symmetrically expanded activated T cell clones in MRL/lpr and NZB/W F1 lupus model mice. Clin. Exp. Immunol. 136: 448-455.
13. Xu, L., L. Zhang, Y. Yi, H. K. Kang, and S. K. Datta. 2004. Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat. Med. 10: 411-415.
14. Niculescu, F., P. Nguyen, T. Niculescu, H. Rus, V. Rus, and C. S. Via. 2003. Pathogenic T cells in murine lupus exhibit spontaneous signaling activity through phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. Arthritis Rheum. 48: 1071-1079.
15. Barber, D. F., A. Bartolome, C. Hernandez, J. M. Flores, C. Redondo, C. Fernandez-Arias, M. Camps, T. Ruckle, M. K. Schwarz, S. Rodriguez, et al. 2005. PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11: 933-935.
16. Borlado, L. R., C. Redondo, B. Alvarez, C. Jimenez, L. M. Criado, J. Flores, M. A. Marcos, C. Martinez-A, D. Balomenos, and A. C. Carrera. 2000. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J. 14: 895-903.
17. Mendlovic, S., S. Brocke, Y. Shoenfeld, M. Ben-Bassat, A. Meshorer, R. Bakimer, and E. Mozes. 1988. Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc. Natl. Acad. Sci. USA 85: 2260-2264.
18. Waisman, A., S. Mendlovic, P. J. Ruiz, H. Zinger, A. Meshorer, and E. Mozes. 1993. The role of the 16/6 idiotype network in the induction and manifestations of systemic lupus erythematosus. Int. Immunol. 5: 1293-1300.
19. Waisman, A., P. J. Ruiz, E. Israeli, E. Eilat, S. Konen-Waisman, H. Zinger, M. Dayan, and E. Mozes. 1997. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc. Natl. Acad. Sci. USA 94: 4620-4625.
20. Zinger, H., E. Eilat, A. Meshorer, and E. Mozes. 2003. Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZB x NZW)F(1) mice via active suppression. Int. Immunol. 15: 205-214.
21. Eilat, E., M. Dayan, H. Zinger, and E. Mozes. 2001. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 98: 1148-1153.
22. Eilat, E., H. Zinger, A. Nyska, and E. Mozes. 2000. Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1- and CDR3-based peptides of a pathogenic autoantibody. J. Clin. Immunol. 20: 268-278.
23. Luger, D., M. Dayan, H. Zinger, J. P. Liu, and E. Mozes. 2004. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J. Clin. Immunol. 24: 579-590.
24. Sela, U., R. Hershkoviz, L. Cahalon, O. Lider, and E. Mozes. 2005. Downregulation of stromal cell-derived factor-1-α-induced T cell chemotaxis by a peptide based on the complementarity-determining region 1 of an anti-DNA autoantibody via up-regulation of TGFβ secretion. J. Immunol. 174: 302-309.
25. Sela, U., N. Mauermann, R. Hershkoviz, H. Zinger, M. Dayan, L. Cahalon, J. P. Liu, E. Mozes, and O. Lider. 2005. The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF-mediated suppression of LFA-1 and CD44 expression and function. J. Immunol. 175: 7255-7263.
26. Sela, U., M. Dayan, R. Hershkoviz, L. Cahalon, O. Lider, and E. Mozes. 2006. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses. Eur. J. Immunol. 36: 2971-2980.
27. Tokano, Y., S. Morimoto, H. Kaneko, H. Amanoo, K. Nozawa, Y. Takasaki, and H. Hashimoto. 1999. Level of IL-12 in the sera of patients with systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. Clin. Exp. Immunol. 116: 169-173.
28. Waisman, A., Y. Shoenfeld, M. Blank, P. J. Ruiz, and E. Mozes. 1995. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int. Immunol. 7: 689-696.
29. Jones, R. G., M. Parsons, M. Bonnard, V. S. Chan, W. C. Yeh, J. R. Woodgett, and P. S. Ohashi. 2000. Protein kinase B regulates T lymphocyte survival, nuclear factor κB activation, and Bcl-X(L) levels in vivo. J. Exp. Med. 191: 1721-1734.
30. King, C. G., T. Kobayashi, P. J. Cejas, T. Kim, K. Yoon, G. K. Kim, E. Chiffoleau, S. P. Hickman, P. T. Walsh, L. A. Turka, and Y. Choi. 2006. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat. Med. 12: 1088-1092.
31. Ohashi, P. S. 2002. T-cell signalling and autoimmunity: molecular mechanisms of disease. Nat. Rev. Immunol. 2: 427-438.
32. Peng, S. L., J. Moslehi, and J. Craft. 1997. Roles of interferon-γ and interleukin-4 in murine Lupus. J. Clin. Invest. 99: 1936-1946.
33. lpr mice. J. Immunol. 161: 494-503.
34. Ozmen, L., D. Roman, M. Fountoulakis, G. Schmid, B. Ryffel, and G. Garotta. 1995. Experimental therapy for systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-γ receptor inhibits the onset of glomerulonephritis. Eur. J. Immunol. 25: 6-12.
35. Remy, I., A. Montmarquette, and S. W. Michnick. 2004. PKB/Akt modulates TGF-β signalling through a direct interaction with Smad3. Nat. Cell. Biol. 6: 358-365.
36. Conery, A. R., Y. Cao, E. A. Thompson, C. M. Townsend, Jr., T. C. Ko, and K. Luo. 2004. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β induced apoptosis. Nat. Cell. Biol. 6: 366-372.